Aerie Pharmaceuticals, Inc.
August 14, 2019
Casey Kopczynski, PhD, Co-Founder & Chief Scientific Officer speaks for Aerie Pharmaceuticals during the Public Company Showcase at OIS@ASRS 2019. Casey Kopczynski, PhD, Co-Founder & Chief Scientific Officer, says Aerie is focused on bringing innovative treatments to eye disease. They’ve launched two products, Rhopressa and Rocklatan, for the reduction of intraocular pressure in patients with glaucoma. The active ingredient in Rhopressa is netarsudil, a Rho kinase inhibitor, which was the first new mechanism of action drug for glaucoma in over 20 years. The second product, Rocklatan, is a combination of netarsudil with latanoprost. It’s the first product to be approved based on demonstrating superiority to a prostaglandin analog, the most widely prescribed drug class in glaucoma.
August 14, 2019
Casey Kopczynski, PhD, Co-Founder & Chief Scientific Officer speaks for Aerie Pharmaceuticals during the Public Company Showcase at OIS@ASRS 2019. Casey Kopczynski, PhD, Co-Founder & Chief Scientific Officer, says Aerie is focused on bringing innovative treatments to eye disease. They’ve launched two products, Rhopressa and Rocklatan, for the reduction of intraocular pressure in patients with glaucoma. The active ingredient in Rhopressa is netarsudil, a Rho kinase inhibitor, which was the first new mechanism of action drug for glaucoma in over 20 years. The second product, Rocklatan, is a combination of netarsudil with latanoprost. It’s the first product to be approved based on demonstrating superiority to a prostaglandin analog, the most widely prescribed drug class in glaucoma.